and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte ...

Pasithea Therapeutics (KTTA) announced that the external Safety Review Committee recommended that the Company’s Phase 1 clinical trial of ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

MIAMI - Pasithea Therapeutics Corp. (NASDAQ: KTTA), a micro-cap biotech firm with a market capitalization of $2.63 million focusing on developing treatments for central nervous system disorders and ...

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

After hours: February 7 at 6:46:14 PM EST Loading Chart for VSTM ...

Day of Atonement; the scapegoat; the eating of blood forbidden; civil and religious laws; immorality forbidden We should also forgive and choose not to remember offenses against ourselves or others.

Upcoming events RAeS Flight Operations Conference 2025: Single Pilot Operations - Logical Progression or a Step Too Far? The RAeS Flight Operations Conference 2025 will gather industry leaders from ...